First-in-human CorWave LVAS for advanced heart failure

First In Human Clinical Study of the CorWave Left Ventricular Assist System for the Treatment of Patients With Advanced Heart Failure

This trial will test a new CorWave left ventricular assist system (LVAS) in adults with advanced heart failure who are eligible for heart transplantation.

Quick facts

• Phase: Not applicable
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: CorWave (Industry-sponsored)
• Locations: 2 sites (Sydney, New South Wales and 1 other locations)
• Trial ID: NCT06907017 on ClinicalTrials.gov

What this trial studies

This is a prospective, multicenter, non-randomized first-in-human interventional trial of the CorWave LVAS to characterize device safety and effectiveness. Eligible participants are adults 18–74 with reduced ejection fraction and either inotrope dependence or low cardiac index despite guideline-directed medical therapy, and who are transplant-eligible. Enrolled patients will receive an LVAS implant and be followed for clinical outcomes and device performance at participating Australian centers. Key exclusion criteria include heart failure from uncorrected thyroid disease, restrictive or infiltrative cardiomyopathies, significant pericardial disease, or technical factors that make surgery unacceptably risky.

Who should consider this trial

Good fit: Ideal candidates are adults (18–74 years) with BSA ≥1.2 m2, LVEF ≤35%, who are inotrope-dependent or have a cardiac index <2.2 L/min/m2 despite therapy, and who are eligible for heart transplantation.

Not a fit: Patients with heart failure caused by uncorrected thyroid disease, obstructive or restrictive/infiltrative cardiomyopathies, significant pericardial disease, or those with prohibitively high surgical risk are unlikely to benefit from this device.

Why it matters

Potential benefit: If successful, the CorWave LVAS could improve circulation and symptoms and serve as a bridge to transplant for eligible patients with advanced heart failure.

How similar studies have performed: While mechanical circulatory support with LVADs has established clinical benefit, the CorWave LVAS is a first-in-human device and its specific safety and effectiveness have not been previously demonstrated in clinical trials.

Eligibility criteria

Inclusion Criteria:

* Subject or legal representative has signed Informed Consent Form
* Age \> 18 and \< 75 years old
* Body Surface Area (BSA) ≥ 1.2 m2
* Left Ventricular Ejection Fraction (LVEF) ≤ 35%
* Inotrope dependent OR
* Cardiac Index (CI) \< 2.2 L/min/m2, while not on inotropes and subjects must also meet one of the following criteria:

  * On Guideline Directed Medical Therapy (GDMT) for at least 45 out of the last 60 days and are failing to respond.
  * Advanced heart failure (Class III or Class IV for at least 14 days AND support from short term mechanical circulatory support for up to 7 days).
* Females of childbearing age must agree to use adequate contraception.
* Patient must be eligible for heart transplantation.

Exclusion Criteria:

* Heart failure (HF) due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis or restrictive cardiomyopathy.
* Technical obstacles which pose an inordinately high surgical risk, in the judgment of the Investigator
* Ongoing mechanical circulatory support (MCS) other than IABP or micro axial pumps
* INTERMACS Class I patients
* Subject is on a ventilator
* Subject is pregnant or breastfeeding
* Presence of a mechanical aortic valve that will not be converted to a bioprosthesis at the time of LVAD implant
* History of any organ transplant
* Platelet count \< 100,000/μl
* Psychiatric disease/disorder, illicit drug use, irreversible cognitive dysfunction or psychosocial issues that are likely to impair compliance with the study protocol and LVAD management
* History of confirmed untreated abdominal aortic aneurysm (AAA) \> 5 cm in diameter within 6 months of enrollment
* Presence of an active, uncontrolled infection
* Intolerance to anticoagulant or antiplatelet therapies or any other peri/post-operative therapy the investigator will require based upon the patient's health status
* Presence of any one of the following risk factors for indications of severe end organ dysfunction or failure:
* An INR ≥ 2.0 not due to anticoagulation therapy
* Total bilirubin \> 43 µmol/L (2.5 mg/dL), liver function tests greater than 3 times the establish laboratory normal, including Serum Albumin below 3.5 g/dl, shock liver, or biopsy proven liver cirrhosis
* History of severe chronic obstructive pulmonary disease (COPD) and restrictive disease (fibrosis); FEV1 \< 50%, a total FEV1 below 1000 mL and a DLCO \< 50% predicted.
* Fixed pulmonary hypertension with a most recent PVR ≥ 8 Wood units that is unresponsive to pharmacologic intervention
* History of stroke within 90 days prior to enrollment, or a history of cerebrovascular disease with significant (\> 50%) uncorrected carotid stenosis
* Serum creatinine ≥ 221 µmol/L (2.5 mg/dL) or the need for chronic renal replacement therapy.
* Ongoing patient malnutrition evidenced by nonintentional weight loss of greater than 5% of body mass in the previous 30 days, prealbumin \< 16 mg/dL, or Mini Nutritional Assessment score \< 17.
* Poorly controlled diabetes mellitus or a hemoglobin A1c \> 8.5%.
* Significant peripheral vascular disease (PVD) accompanied by rest pain or extremity ulceration.
* Patient has severe aortic insufficiency without plans for correction during pump implant.
* Planned Bi-VAD support prior to enrollment.
* Patient has known hypo or hyper coagulable states such as disseminated intravascular coagulation and heparin induced thrombocytopenia.
* Participation in any other clinical investigation that is likely to confound study results or affect the study.
* Any condition other than HF that could limit survival to less than 12 months.
* Acute myocardial infarction within 14 days of implant as diagnosed by ST elevation (STEMI) changes on ECG, diagnostic biomarkers, and hemodynamic abnormalities. Planned or carried out coronary revascularizations (including PCI requiring (dual) antiplatelet therapies).
* Pulmonary embolus within 6 weeks of implant as documented by computed tomography (CT) scan or nuclear scan.
* Subject is unwilling or unable to comply with trial requirements.

Where this trial is running

Sydney, New South Wales and 1 other locations

• St Vincent's Hospital Sydney — Sydney, New South Wales, Australia (Recruiting)
• Bayside Health — Melbourne, Victoria, Australia (Recruiting)

Study contacts

• Study coordinator: Gabriella Giaquinta

Conditions Advanced Heart Failure